Smilow Cancer Hospital at Guilford
Yale New Haven Shoreline Medical Center
111 Goose Lane
Guilford, CT 06437
- Smilow Cancer Hospital at GuilfordYale New Haven Shoreline Medical Center111 Goose LaneGuilford, CT 06437
Mariya Rozenblit, MD
Medical Oncology
Patient type treated
Adult
Accepting new patients
Yes
Referral required
Not Applicable
Biography
Mariya Rozenblit, MD, is a medical oncologist who specializes in treating patients with different types of breast cancer, from ductal carcinoma in situ (DCIS), the most common type of breast cancer, to metastatic breast cancer, or stage IV breast cancer.
Dr. Rozenblit research focuses on biomarker-driven trial development in breast cancer. These types of clinical trials allow researchers to investigate how patients (including those with different cancer mutations) respond to available medications. For example, Dr. Rozenblit co-authored a study that found patients younger than 40 with advanced breast cancer often suffer a worse prognosis and more severe symptoms than older patients.
She has received the American Society of Clinical Oncology’s Conquer Cancer Foundation’s Young Investigator Award and the Susan G. Komen Cancer Catalyst Research Grant. Dr. Rozenblit is an assistant professor of medicine (medical oncology) at Yale School of Medicine.
Titles
- Assistant Professor of Medicine (Medical Oncology)
Education & Training
- Internal Medicine ResidentNYU Langone Medical Center (2018)
- MDIcahn School of Medicine at Mount Sinai (2015)
- BAColumbia University, Biology (2009)
Additional Information
Honors & Recognitions
- Susan G. Komen Career Catalyst Award: (2022)
- ASCO Conquer Cancer Foundation Young Investigator Award: (2020)
Publications
- Fanucci K, Rozenblit M, Quintanilha J, Graf R, Fischbach N, Pelletier M, Sivapiragasam A, Kumar P, Kallem M, Sokol E, Sivakumar S, Pavlick D, Ross J, Lustberg M, Pusztai L. Ultra-high tumor mutation burden breast cancer: genomic profiling and real-world immunotherapy results. Npj Breast Cancer 2026 PMID: 42162005, DOI: 10.1038/s41523-026-00965-6.
- Abdou Y, Rozenblit M, Trapani D, Zerdes I, Boudreau E, Zhou Y, Adam V, Barrios C, Bousrih C, Branch V, Carey L, Cameron D, Chen S, Chua B, Davidson N, Domchek S, El-Abed S, El-Ashry D, Flowers M, Foldi J, Garber J, Goulioti T, Hodgdon C, Hung J, Klar N, Norton L, Parajuli R, Piccart M, Pollastro T, Santa-Maria C, Schumacher-Wulf E, Stecklein S, Thulin A, Tovey H, Winer E, Wolff A, Lin N, O’Reilly S. Invest where impact begins: recommendations from Breast Cancer Research Foundation Early Career Investigator Working Group (Part 1 of 2). Npj Breast Cancer 2026, 12: 69. PMID: 42115634, PMCID: PMC13161217, DOI: 10.1038/s41523-026-00940-1.
- Odzer N, Wei W, Lustberg M, Pusztai L, Rozenblit M. Current Management Practices of De Novo Oligometastatic Breast Cancer: Real-World Data From a Physician Survey. JCO Oncology Practice 2026, op2500413. PMID: 41616223, DOI: 10.1200/op-25-00413.
- Suwalska A, Rozenblit M, Harigopal M, Dai J, Liu M, Townsend J, Marczyk M, Pusztai L. Mutational landscape of normal breast tissues adjacent to invasive breast cancer. Cell Reports Medicine 2026, 7: 102543. PMID: 41512875, PMCID: PMC12866091, DOI: 10.1016/j.xcrm.2025.102543.
- Lee S, Kahn A, Rozenblit M, George M, Ortiz C, Lustberg M. HER2‐Targeted Antibody‐Drug Conjugate Toxicities in Breast Cancer. Cancer Medicine 2025, 14: e71415. PMID: 41361931, PMCID: PMC12685761, DOI: 10.1002/cam4.71415.
- Ajjawi I, Rozenblit M, Rios-Hoyo A, Lustberg M. Prognostic Value of Circulating Tumor DNA in HR+/HER2− Stage I–III Breast Cancer: A Systematic Review. Cancers 2025, 17: 2831. PMID: 40940926, PMCID: PMC12427406, DOI: 10.3390/cancers17172831.
- Brennan M, Plichta J, Rozenblit M, Flanagan M. Surgeon Attitudes on the Management of de novo Oligometastatic Breast Cancer. Annals Of Surgical Oncology 2025, 32: 9478-9479. PMID: 40767935, DOI: 10.1245/s10434-025-17912-7.
- Pusztai L, Rozenblit M, Dubsky P, Bachelot T, Kirby A, Linderholm B, White J, Chmura S, Carey L, Chua B, Miller K. Erratum: De Novo Oligometastatic Breast Cancer. Journal Of Clinical Oncology 2025, 43: 2758-2758. PMID: 40690726, PMCID: PMC12521985, DOI: 10.1200/jco-25-01626.
- Jeon J, Chen K, Madison R, Schrock A, Sokol E, Levy M, Rozenblit M, Huang R, Pusztai L. Genomic landscape and homologous recombination repair deficiency signature in stage I-III and de novo stage IV primary breast cancers. The Oncologist 2025, 30: oyaf089. PMID: 40421962, PMCID: PMC12107548, DOI: 10.1093/oncolo/oyaf089.
- Abraham S, Parekh J, Lee S, Afrin H, Rozenblit M, Blenman K, Perry R, Ferrucci L, Liu J, Irwin M, Lustberg M. Accelerated Aging in Cancer and Cancer Treatment: Current Status of Biomarkers. Cancer Medicine 2025, 14: e70929. PMID: 40322791, PMCID: PMC12051034, DOI: 10.1002/cam4.70929.
- Lambertini M, Blondeaux E, Tomasello L, Agostinetto E, Hamy A, Kim H, Franzoi M, Bernstein-Molho R, Hilbers F, Pogoda K, Wildiers H, Bajpai J, Ignatiadis M, Moore H, Partridge A, Phillips K, Toss A, Rousset-Jablonski C, Criscitiello C, Renaud T, Ferrari A, Paluch-Shimon S, Fruscio R, Cui W, Wong S, Vernieri C, Ruddy K, Dieci M, Matikas A, Rozenblit M, Villarreal-Garza C, De Marchis L, Puglisi F, Rodriguez-Wallberg K, Duhoux F, Livraghi L, Bruzzone M, Boni L, Balmaña J. Clinical Behavior of Breast Cancer in Young BRCA Carriers and Prediagnostic Awareness of Germline BRCA Status. Journal Of Clinical Oncology 2025, 43: 1706-1719. PMID: 39993249, PMCID: PMC12058366, DOI: 10.1200/jco-24-01334.
- Dai J, Rozenblit M, Li X, Shan N, Wang Y, Mane S, Marczyk M, Pusztai L. Genomic alterations in normal breast tissues preceding breast cancer diagnosis. Breast Cancer Research 2025, 27: 60. PMID: 40264151, PMCID: PMC12013151, DOI: 10.1186/s13058-025-02018-5.
- Rozenblit M, Qing T, Ye Y, Zhao H, Hofstatter E, Singh V, Reisenbichler E, Murray M, Pusztai L. Rare germline variants in cancer-relevant genes are associated with breast cancer risk in young women with high-risk family history. Breast Cancer Research And Treatment 2024, 209: 21-26. PMID: 39602012, DOI: 10.1007/s10549-024-07560-y.
- Lambertini M, Blondeaux E, Agostinetto E, Hamy A, Kim H, Di Meglio A, Bernstein Molho R, Hilbers F, Pogoda K, Carrasco E, Punie K, Bajpai J, Ignatiadis M, Moore H, Phillips K, Toss A, Rousset-Jablonski C, Peccatori F, Renaud T, Ferrari A, Paluch-Shimon S, Fruscio R, Cui W, Wong S, Vernieri C, Ruddy K, Dieci M, Matikas A, Rozenblit M, Villarreal-Garza C, De Marchis L, Del Mastro L, Puglisi F, Del Pilar Estevez-Diz M, Rodriguez-Wallberg K, Mrinakova B, Meister S, Livraghi L, Clatot F, Yerushalmi R, De Angelis C, Sánchez-Bayona R, Meattini I, Cichowska-Cwalińska N, Berlière M, Salama M, De Giorgi U, Sonnenblick A, Chiodi C, Lee Y, Maria C, Azim H, Boni L, Partridge A, de Azambuja E, Molinelli C, Paesmans M, Ameye L, Amant F, Brems H, Han S, Hatse S, Nevelsteen I, Neven P, Smeets A, Van Rompuy C, Wildiers H, Duhoux F, Giugliano F, Criscitiello C, Borea R, Arecco L, Chirco A, Bini F, Venturelli M, Cortesi L, Ponzone R, Tomasi Cont N, Balmaña J, Graffeo R, Luna Pais H, Mohar A, Palacios T, Da Ros L, Miolo G, Garutti M, Pastò B, Spazzapan S, Viel A, Pérez-Fidalgo A, Colombo Bonadio R, Peretz-Yablonski T, Anghelone C, Della Valle A, Campanella M, Guarneri V, Bas R, Heudel P, Tredan O, de Talouet S, Bonadona V, Lasset C, Acheritogaray M, Senechal C, Mariño M, Córdoba O, Feldman D, Pesce R, Allemand C, Riggi C, Iriarte M, Cortés Salgado A, Cortes J, Gion M, Saavedra C, Rodriguez A, Adamo B, Prat A, Hester A, Dunckelmann S, Harbeck N, Marhold M, Bartsch R, Mannsbarth C, Popovic L, Božović-Spasojević I, Krivokuca A, Dimitrijevic M, Visani L, Bettazzi B, Livi L, Sposetti C, Sini V, Rognone A, Bianchini G, Patricelli M, Rabaiotti E, Gentilini O, Fontana A, Acconci G, Baldacci E, Bianchini G, Pistelli M, Linn S, Kleiterp S, Moha D, Sarin R, Sekar A, Atzori F, Loi F, Dessì M, O’Connor S, Nesci S, James P, Michael C, Couch F, Olson J, Larson N, Yadav S, Lopetegui N, Carey L, Abdou Y, Zagami P, Di Rocco R, Baldassarri M, Bengala C, Mariamidze E, Graff S, Haddad S, Safran E, Vasconcelos de Matos L, Ferreira A, Negri S, Dell'Oro C, Inzoli A, Costa C, Marchetta L, Lustberg M, Blansky D, Jeon J, Ansari N, Aguilar-y-Mendez D, Woodruff T, Swain M, Miller M, Leach R, Fabi A, Palazzo A, Paris I, Kufel-Grabowska J, Synowiec A, Hancinova M, Tarbaj L, Sokolović E, Bešlija S, Cerić T, Hasanbegović B, Foulkes W, Bianchi M, Tolosa P, Alvaro L, Eriksson Bergman L, Antone N, Damian C. Pregnancy After Breast Cancer in Young BRCA Carriers. JAMA: The Journal Of The American Medical Association 2024, 331: 49-59. PMID: 38059899, PMCID: PMC10704340, DOI: 10.1001/jama.2023.25463.
- Blansky D, Ansari N, Gao L, Sokol E, Sivakumar S, Huang R, Pelletier M, Levy M, Pavlick D, Danziger N, Ross J, Lustberg M, Rozenblit M. Prevalence of targetable genomic alterations in young women with advanced breast cancer: a cross-sectional study. Breast Cancer Research And Treatment 2023, 204: 181-185. PMID: 37999916, DOI: 10.1007/s10549-023-07179-5.
- Lin H, Can T, Kahn A, Flannery C, Hoag J, Akkunuri A, Bailey H, Baehner R, Pusztai L, Rozenblit M. Molecular Characterization of HER2-Low Invasive Breast Carcinoma by Quantitative RT-PCR Using Oncotype DX Assay. The Oncologist 2023, 28: e973-e976. PMID: 37656608, PMCID: PMC10546821, DOI: 10.1093/oncolo/oyad249.
- Pusztai L, Rozenblit M, Dubsky P, Bachelot T, Kirby A, Linderholm B, White J, Chmura S, Carey L, Chua B, Miller K. De Novo Oligometastatic Breast Cancer. Journal Of Clinical Oncology 2023, 41: 5237-5241. PMID: 37607325, PMCID: PMC10691789, DOI: 10.1200/jco.23.00911.
- Minteer C, Thrush K, Gonzalez J, Niimi P, Rozenblit M, Rozowsky J, Liu J, Frank M, McCabe T, Sehgal R, Higgins-Chen A, Hofstatter E, Pusztai L, Beckman K, Gerstein M, Levine M. More than bad luck: Cancer and aging are linked to replication-driven changes to the epigenome. Science Advances 2023, 9: eadf4163. PMID: 37467337, PMCID: PMC10355820, DOI: 10.1126/sciadv.adf4163.
- Moreira-Dinzey J, Zhan H, Rozenblit M, Krishnamurti U, Harigopal M, Zhong M, Liang Y. The correlation of ESR1 genetic aberrations with estrogen receptor and progesterone receptor status in metastatic and primary estrogen receptor-positive breast carcinomas. Human Pathology 2023, 137: 56-62. PMID: 37127079, DOI: 10.1016/j.humpath.2023.04.017.
- Qing T, Karn T, Rozenblit M, Foldi J, Marczyk M, Shan N, Blenman K, Holtrich U, Kalinsky K, Meric-Bernstam F, Pusztai L. Molecular differences between younger versus older ER-positive and HER2-negative breast cancers. Npj Breast Cancer 2022, 8: 119. PMID: 36344517, PMCID: PMC9640562, DOI: 10.1038/s41523-022-00492-0.
- Rozenblit M, Blenman K, Harigopal M, Reisenbichler E, Singh K, Qing T, Ibrahim E, Ramkissoon S, Asmelash S, Lin HK, Roberts M, Ross J, Huang RSP, Pusztai L. PD-L1 protein expression in relation to recurrence score values in early-stage ER + breast cancer. Breast Cancer Research And Treatment 2022, 196: 221-227. PMID: 36028784, DOI: 10.1007/s10549-022-06712-2.
- Qing T, Mohsen H, Cannataro VL, Marczyk M, Rozenblit M, Foldi J, Murray M, Townsend J, Kluger Y, Gerstein M, Pusztai L. Cancer Relevance of Human Genes. Journal Of The National Cancer Institute 2022, 114: 988-995. PMID: 35417011, PMCID: PMC9275765, DOI: 10.1093/jnci/djac068.
- Blenman KRM, Marczyk M, Karn T, Qing T, Li X, Gunasekharan V, Yaghoobi V, Bai Y, Ibrahim EY, Park T, Silber A, Wolf DM, Reisenbichler E, Denkert C, Sinn BV, Rozenblit M, Foldi J, Rimm DL, Loibl S, Pusztai L. Predictive markers of response to neoadjuvant durvalumab with nab-paclitaxel and dose dense doxorubicin/cyclophosphamide in basal-like triple negative breast cancer. Clinical Cancer Research 2022, 28: 2587-2597. PMID: 35377948, PMCID: PMC9464605, DOI: 10.1158/1078-0432.ccr-21-3215.
- Rozenblit M, Lustberg MB. Sacituzumab govitecan: ascending the treatment algorithm in triple negative breast cancer. Annals Of Translational Medicine 2022, 0: 0-0. PMID: 35530962, PMCID: PMC9073796, DOI: 10.21037/atm-22-484.
- Rozenblit M, Hofstatter E, Liu Z, O’Meara T, Storniolo AM, Dalela D, Singh V, Pusztai L, Levine M. Evidence of accelerated epigenetic aging of breast tissues in patients with breast cancer is driven by CpGs associated with polycomb-related genes. Clinical Epigenetics 2022, 14: 30. PMID: 35209953, PMCID: PMC8876160, DOI: 10.1186/s13148-022-01249-z.
- Foldi J, Rozenblit M, Park TS, Knowlton CA, Golshan M, Moran M, Pusztai L. Optimal Management for Residual Disease Following Neoadjuvant Systemic Therapy. Current Treatment Options In Oncology 2021, 22: 79. PMID: 34213636, DOI: 10.1007/s11864-021-00879-4.
- Rozenblit M, Mun S, Soulos P, Adelson K, Pusztai L, Mougalian S. Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy. Breast Cancer Research 2021, 23: 14. PMID: 33514405, PMCID: PMC7844919, DOI: 10.1186/s13058-021-01394-y.
- Rozenblit M, Huang R, Danziger N, Hegde P, Alexander B, Ramkissoon S, Blenman K, Ross JS, Rimm DL, Pusztai L. Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers. Journal For ImmunoTherapy Of Cancer 2020, 8: e001558. PMID: 33239417, PMCID: PMC7689582, DOI: 10.1136/jitc-2020-001558.
- Rozenblit M, Hendrickx W, Heguy A, Chiriboga L, Loomis C, Ray K, Darvishian F, Egeblad M, Demaria S, Marincola FM, Bedognetti D, Adams S. Transcriptomic profiles conducive to immune-mediated tumor rejection in human breast cancer skin metastases treated with Imiquimod. Scientific Reports 2019, 9: 8572. PMID: 31189943, PMCID: PMC6561945, DOI: 10.1038/s41598-019-42784-9.
- McFarland DC, Naikan J, Rozenblit M, Mandeli J, Bleiweiss I, Tiersten A. Changes in Pathological Complete Response Rates after Neoadjuvant Chemotherapy for Breast Carcinoma over Five Years. Journal Of Oncology 2016, 2016: 4324863. PMID: 27382369, PMCID: PMC4921638, DOI: 10.1155/2016/4324863.
- Suárez-Fariñas M, Ungar B, da Rosa J, Ewald DA, Rozenblit M, Gonzalez J, Xu H, Zheng X, Peng X, Estrada YD, Dillon SR, Krueger JG, Guttman-Yassky E. RNA sequencing atopic dermatitis transcriptome profiling provides insights into novel disease mechanisms with potential therapeutic implications. The Journal Of Allergy And Clinical Immunology 2015, 135: 1218-1227. PMID: 25840722, DOI: 10.1016/j.jaci.2015.03.003.
- Rozenblit M, Guttman‐Yassky E. Contact Dermatitis. 2015, 25-35. DOI: 10.1002/9781118609125.ch3.
- da Rosa J, Malajian D, Shemer A, Rozenblit M, Dhingra N, Czarnowicki T, Khattri S, Ungar B, Finney R, Xu H, Zheng X, Estrada YD, Peng X, Suárez-Fariñas M, Krueger JG, Guttman-Yassky E. Patients with atopic dermatitis have attenuated and distinct contact hypersensitivity responses to common allergens in skin. The Journal Of Allergy And Clinical Immunology 2015, 135: 712-720. PMID: 25583101, DOI: 10.1016/j.jaci.2014.11.017.
- Esaki H, Ewald DA, Ungar B, Rozenblit M, Zheng X, Xu H, Estrada YD, Peng X, Mitsui H, Litman T, Suárez-Fariñas M, Krueger JG, Guttman-Yassky E. Identification of novel immune and barrier genes in atopic dermatitis by means of laser capture microdissection. The Journal Of Allergy And Clinical Immunology 2015, 135: 153-163. PMID: 25567045, PMCID: PMC4452382, DOI: 10.1016/j.jaci.2014.10.037.
- Rozenblit M, Suarez-Farinas M, Shemer A, Khattri S, Gilleaudeau P, Sullivan-Whalen M, Zheng X, Xu H, Cardinale I, Krueger JG, Guttman-Yassky E. Residual genomic profile after cyclosporine treatment may offer insights into atopic dermatitis reoccurrence. The Journal Of Allergy And Clinical Immunology 2014, 134: 955-957. PMID: 24996261, PMCID: PMC4281263, DOI: 10.1016/j.jaci.2014.05.024.
- Khattri S, Shemer A, Rozenblit M, Dhingra N, Czarnowicki T, Finney R, Gilleaudeau P, Sullivan-Whalen M, Zheng X, Xu H, Cardinale I, de Guzman Strong C, Gonzalez J, Suárez-Fariñas M, Krueger JG, Guttman-Yassky E. Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology. The Journal Of Allergy And Clinical Immunology 2014, 133: 1626-1634. PMID: 24786238, PMCID: PMC4122665, DOI: 10.1016/j.jaci.2014.03.003.
- Dhingra N, Shemer A, da Rosa J, Rozenblit M, Fuentes-Duculan J, Gittler JK, Finney R, Czarnowicki T, Zheng X, Xu H, Estrada YD, Cardinale I, Suárez-Fariñas M, Krueger JG, Guttman-Yassky E. Molecular profiling of contact dermatitis skin identifies allergen-dependent differences in immune response. The Journal Of Allergy And Clinical Immunology 2014, 134: 362-372. PMID: 24768652, DOI: 10.1016/j.jaci.2014.03.009.
- Rozenblit M. 2011 Runner-Up Essay Incentives for Medical School Students to Practice Primary Care through the Lens of John Rawls. The AMA Journal Of Ethic 2012, 14: 970-976. PMID: 23351945, DOI: 10.1001/virtualmentor.2012.14.12.conl4-1212.
- Rozenblit M, Lebwohl M. New biologics for psoriasis and psoriatic arthritis. Dermatologic Therapy 2009, 22: 56-60. PMID: 19222517, DOI: 10.1111/j.1529-8019.2008.01216.x.
- Wang G, Drake C, Rozenblit M, Zhou P, Alves S, Herrick S, Hayashi S, Warrier S, Iadecola C, Milner T. Evidence that estrogen directly and indirectly modulates C1 adrenergic bulbospinal neurons in the rostral ventrolateral medulla. Brain Research 2006, 1094: 163-178. PMID: 16696957, DOI: 10.1016/j.brainres.2006.03.089.
- Spuls P, Rozenblit M, Lebwohl M. Retrospective study of the efficacy of narrowband UVB and acitretin. Journal Of Dermatological Treatment 2003, 14: 17-20. PMID: 14578094, DOI: 10.1080/jdt.14.s2.17.20.
- Maryles S, Rozenblit M, Lebwohl M. Transition from methotrexate and cyclosporine to other therapies including retinoids, ultraviolet light and biologic agents in the management of patients with psoriasis. Journal Of Dermatological Treatment 2003, 14: 7-16. PMID: 14578093, DOI: 10.1080/jdt.14.s2.7.16.
- Spuls P, Rozenblit M, Lebwohl M. Retrospective study of the efficacy of narrowband UVB and acitretin. Journal Of Dermatological Treatment 2003, 14: 17-20. DOI: 10.1080/738528794.
- Maryles S, Rozenblit M, Lebwohl M. Transition from methotrexate and cyclosporine to other therapies including retinoids, ultraviolet light and biologic agents in the management of patients with psoriasis. Journal Of Dermatological Treatment 2000, 14: 7-16. DOI: 10.1080/738528793.
- Maryles S, Rozenblit M, Lebwohl M. Transition from methotrexate and cyclosporine to other therapies including retinoids, ultraviolet light and biologic agents in the management of patients with psoriasis. Journal Of Dermatological Treatment 2000, 14: 7-16. DOI: 10.1080/753995509.
Departments and Programs
Locations
Smilow Cancer Hospital at Guilford
Yale New Haven Shoreline Medical Center
111 Goose Lane
Guilford, CT 06437
- Smilow Cancer Hospital at GuilfordYale New Haven Shoreline Medical Center111 Goose LaneGuilford, CT 06437
Biography
Mariya Rozenblit, MD, is a medical oncologist who specializes in treating patients with different types of breast cancer, from ductal carcinoma in situ (DCIS), the most common type of breast cancer, to metastatic breast cancer, or stage IV breast cancer.
Dr. Rozenblit research focuses on biomarker-driven trial development in breast cancer. These types of clinical trials allow researchers to investigate how patients (including those with different cancer mutations) respond to available medications. For example, Dr. Rozenblit co-authored a study that found patients younger than 40 with advanced breast cancer often suffer a worse prognosis and more severe symptoms than older patients.
She has received the American Society of Clinical Oncology’s Conquer Cancer Foundation’s Young Investigator Award and the Susan G. Komen Cancer Catalyst Research Grant. Dr. Rozenblit is an assistant professor of medicine (medical oncology) at Yale School of Medicine.
Titles
- Assistant Professor of Medicine (Medical Oncology)
Education & Training
- Internal Medicine ResidentNYU Langone Medical Center (2018)
- MDIcahn School of Medicine at Mount Sinai (2015)
- BAColumbia University, Biology (2009)
Additional Information
Honors & Recognitions
- Susan G. Komen Career Catalyst Award: (2022)
- ASCO Conquer Cancer Foundation Young Investigator Award: (2020)
Publications
- Fanucci K, Rozenblit M, Quintanilha J, Graf R, Fischbach N, Pelletier M, Sivapiragasam A, Kumar P, Kallem M, Sokol E, Sivakumar S, Pavlick D, Ross J, Lustberg M, Pusztai L. Ultra-high tumor mutation burden breast cancer: genomic profiling and real-world immunotherapy results. Npj Breast Cancer 2026 PMID: 42162005, DOI: 10.1038/s41523-026-00965-6.
- Abdou Y, Rozenblit M, Trapani D, Zerdes I, Boudreau E, Zhou Y, Adam V, Barrios C, Bousrih C, Branch V, Carey L, Cameron D, Chen S, Chua B, Davidson N, Domchek S, El-Abed S, El-Ashry D, Flowers M, Foldi J, Garber J, Goulioti T, Hodgdon C, Hung J, Klar N, Norton L, Parajuli R, Piccart M, Pollastro T, Santa-Maria C, Schumacher-Wulf E, Stecklein S, Thulin A, Tovey H, Winer E, Wolff A, Lin N, O’Reilly S. Invest where impact begins: recommendations from Breast Cancer Research Foundation Early Career Investigator Working Group (Part 1 of 2). Npj Breast Cancer 2026, 12: 69. PMID: 42115634, PMCID: PMC13161217, DOI: 10.1038/s41523-026-00940-1.
- Odzer N, Wei W, Lustberg M, Pusztai L, Rozenblit M. Current Management Practices of De Novo Oligometastatic Breast Cancer: Real-World Data From a Physician Survey. JCO Oncology Practice 2026, op2500413. PMID: 41616223, DOI: 10.1200/op-25-00413.
- Suwalska A, Rozenblit M, Harigopal M, Dai J, Liu M, Townsend J, Marczyk M, Pusztai L. Mutational landscape of normal breast tissues adjacent to invasive breast cancer. Cell Reports Medicine 2026, 7: 102543. PMID: 41512875, PMCID: PMC12866091, DOI: 10.1016/j.xcrm.2025.102543.
- Lee S, Kahn A, Rozenblit M, George M, Ortiz C, Lustberg M. HER2‐Targeted Antibody‐Drug Conjugate Toxicities in Breast Cancer. Cancer Medicine 2025, 14: e71415. PMID: 41361931, PMCID: PMC12685761, DOI: 10.1002/cam4.71415.
- Ajjawi I, Rozenblit M, Rios-Hoyo A, Lustberg M. Prognostic Value of Circulating Tumor DNA in HR+/HER2− Stage I–III Breast Cancer: A Systematic Review. Cancers 2025, 17: 2831. PMID: 40940926, PMCID: PMC12427406, DOI: 10.3390/cancers17172831.
- Brennan M, Plichta J, Rozenblit M, Flanagan M. Surgeon Attitudes on the Management of de novo Oligometastatic Breast Cancer. Annals Of Surgical Oncology 2025, 32: 9478-9479. PMID: 40767935, DOI: 10.1245/s10434-025-17912-7.
- Pusztai L, Rozenblit M, Dubsky P, Bachelot T, Kirby A, Linderholm B, White J, Chmura S, Carey L, Chua B, Miller K. Erratum: De Novo Oligometastatic Breast Cancer. Journal Of Clinical Oncology 2025, 43: 2758-2758. PMID: 40690726, PMCID: PMC12521985, DOI: 10.1200/jco-25-01626.
- Jeon J, Chen K, Madison R, Schrock A, Sokol E, Levy M, Rozenblit M, Huang R, Pusztai L. Genomic landscape and homologous recombination repair deficiency signature in stage I-III and de novo stage IV primary breast cancers. The Oncologist 2025, 30: oyaf089. PMID: 40421962, PMCID: PMC12107548, DOI: 10.1093/oncolo/oyaf089.
- Abraham S, Parekh J, Lee S, Afrin H, Rozenblit M, Blenman K, Perry R, Ferrucci L, Liu J, Irwin M, Lustberg M. Accelerated Aging in Cancer and Cancer Treatment: Current Status of Biomarkers. Cancer Medicine 2025, 14: e70929. PMID: 40322791, PMCID: PMC12051034, DOI: 10.1002/cam4.70929.
- Lambertini M, Blondeaux E, Tomasello L, Agostinetto E, Hamy A, Kim H, Franzoi M, Bernstein-Molho R, Hilbers F, Pogoda K, Wildiers H, Bajpai J, Ignatiadis M, Moore H, Partridge A, Phillips K, Toss A, Rousset-Jablonski C, Criscitiello C, Renaud T, Ferrari A, Paluch-Shimon S, Fruscio R, Cui W, Wong S, Vernieri C, Ruddy K, Dieci M, Matikas A, Rozenblit M, Villarreal-Garza C, De Marchis L, Puglisi F, Rodriguez-Wallberg K, Duhoux F, Livraghi L, Bruzzone M, Boni L, Balmaña J. Clinical Behavior of Breast Cancer in Young BRCA Carriers and Prediagnostic Awareness of Germline BRCA Status. Journal Of Clinical Oncology 2025, 43: 1706-1719. PMID: 39993249, PMCID: PMC12058366, DOI: 10.1200/jco-24-01334.
- Dai J, Rozenblit M, Li X, Shan N, Wang Y, Mane S, Marczyk M, Pusztai L. Genomic alterations in normal breast tissues preceding breast cancer diagnosis. Breast Cancer Research 2025, 27: 60. PMID: 40264151, PMCID: PMC12013151, DOI: 10.1186/s13058-025-02018-5.
- Rozenblit M, Qing T, Ye Y, Zhao H, Hofstatter E, Singh V, Reisenbichler E, Murray M, Pusztai L. Rare germline variants in cancer-relevant genes are associated with breast cancer risk in young women with high-risk family history. Breast Cancer Research And Treatment 2024, 209: 21-26. PMID: 39602012, DOI: 10.1007/s10549-024-07560-y.
- Lambertini M, Blondeaux E, Agostinetto E, Hamy A, Kim H, Di Meglio A, Bernstein Molho R, Hilbers F, Pogoda K, Carrasco E, Punie K, Bajpai J, Ignatiadis M, Moore H, Phillips K, Toss A, Rousset-Jablonski C, Peccatori F, Renaud T, Ferrari A, Paluch-Shimon S, Fruscio R, Cui W, Wong S, Vernieri C, Ruddy K, Dieci M, Matikas A, Rozenblit M, Villarreal-Garza C, De Marchis L, Del Mastro L, Puglisi F, Del Pilar Estevez-Diz M, Rodriguez-Wallberg K, Mrinakova B, Meister S, Livraghi L, Clatot F, Yerushalmi R, De Angelis C, Sánchez-Bayona R, Meattini I, Cichowska-Cwalińska N, Berlière M, Salama M, De Giorgi U, Sonnenblick A, Chiodi C, Lee Y, Maria C, Azim H, Boni L, Partridge A, de Azambuja E, Molinelli C, Paesmans M, Ameye L, Amant F, Brems H, Han S, Hatse S, Nevelsteen I, Neven P, Smeets A, Van Rompuy C, Wildiers H, Duhoux F, Giugliano F, Criscitiello C, Borea R, Arecco L, Chirco A, Bini F, Venturelli M, Cortesi L, Ponzone R, Tomasi Cont N, Balmaña J, Graffeo R, Luna Pais H, Mohar A, Palacios T, Da Ros L, Miolo G, Garutti M, Pastò B, Spazzapan S, Viel A, Pérez-Fidalgo A, Colombo Bonadio R, Peretz-Yablonski T, Anghelone C, Della Valle A, Campanella M, Guarneri V, Bas R, Heudel P, Tredan O, de Talouet S, Bonadona V, Lasset C, Acheritogaray M, Senechal C, Mariño M, Córdoba O, Feldman D, Pesce R, Allemand C, Riggi C, Iriarte M, Cortés Salgado A, Cortes J, Gion M, Saavedra C, Rodriguez A, Adamo B, Prat A, Hester A, Dunckelmann S, Harbeck N, Marhold M, Bartsch R, Mannsbarth C, Popovic L, Božović-Spasojević I, Krivokuca A, Dimitrijevic M, Visani L, Bettazzi B, Livi L, Sposetti C, Sini V, Rognone A, Bianchini G, Patricelli M, Rabaiotti E, Gentilini O, Fontana A, Acconci G, Baldacci E, Bianchini G, Pistelli M, Linn S, Kleiterp S, Moha D, Sarin R, Sekar A, Atzori F, Loi F, Dessì M, O’Connor S, Nesci S, James P, Michael C, Couch F, Olson J, Larson N, Yadav S, Lopetegui N, Carey L, Abdou Y, Zagami P, Di Rocco R, Baldassarri M, Bengala C, Mariamidze E, Graff S, Haddad S, Safran E, Vasconcelos de Matos L, Ferreira A, Negri S, Dell'Oro C, Inzoli A, Costa C, Marchetta L, Lustberg M, Blansky D, Jeon J, Ansari N, Aguilar-y-Mendez D, Woodruff T, Swain M, Miller M, Leach R, Fabi A, Palazzo A, Paris I, Kufel-Grabowska J, Synowiec A, Hancinova M, Tarbaj L, Sokolović E, Bešlija S, Cerić T, Hasanbegović B, Foulkes W, Bianchi M, Tolosa P, Alvaro L, Eriksson Bergman L, Antone N, Damian C. Pregnancy After Breast Cancer in Young BRCA Carriers. JAMA: The Journal Of The American Medical Association 2024, 331: 49-59. PMID: 38059899, PMCID: PMC10704340, DOI: 10.1001/jama.2023.25463.
- Blansky D, Ansari N, Gao L, Sokol E, Sivakumar S, Huang R, Pelletier M, Levy M, Pavlick D, Danziger N, Ross J, Lustberg M, Rozenblit M. Prevalence of targetable genomic alterations in young women with advanced breast cancer: a cross-sectional study. Breast Cancer Research And Treatment 2023, 204: 181-185. PMID: 37999916, DOI: 10.1007/s10549-023-07179-5.
- Lin H, Can T, Kahn A, Flannery C, Hoag J, Akkunuri A, Bailey H, Baehner R, Pusztai L, Rozenblit M. Molecular Characterization of HER2-Low Invasive Breast Carcinoma by Quantitative RT-PCR Using Oncotype DX Assay. The Oncologist 2023, 28: e973-e976. PMID: 37656608, PMCID: PMC10546821, DOI: 10.1093/oncolo/oyad249.
- Pusztai L, Rozenblit M, Dubsky P, Bachelot T, Kirby A, Linderholm B, White J, Chmura S, Carey L, Chua B, Miller K. De Novo Oligometastatic Breast Cancer. Journal Of Clinical Oncology 2023, 41: 5237-5241. PMID: 37607325, PMCID: PMC10691789, DOI: 10.1200/jco.23.00911.
- Minteer C, Thrush K, Gonzalez J, Niimi P, Rozenblit M, Rozowsky J, Liu J, Frank M, McCabe T, Sehgal R, Higgins-Chen A, Hofstatter E, Pusztai L, Beckman K, Gerstein M, Levine M. More than bad luck: Cancer and aging are linked to replication-driven changes to the epigenome. Science Advances 2023, 9: eadf4163. PMID: 37467337, PMCID: PMC10355820, DOI: 10.1126/sciadv.adf4163.
- Moreira-Dinzey J, Zhan H, Rozenblit M, Krishnamurti U, Harigopal M, Zhong M, Liang Y. The correlation of ESR1 genetic aberrations with estrogen receptor and progesterone receptor status in metastatic and primary estrogen receptor-positive breast carcinomas. Human Pathology 2023, 137: 56-62. PMID: 37127079, DOI: 10.1016/j.humpath.2023.04.017.
- Qing T, Karn T, Rozenblit M, Foldi J, Marczyk M, Shan N, Blenman K, Holtrich U, Kalinsky K, Meric-Bernstam F, Pusztai L. Molecular differences between younger versus older ER-positive and HER2-negative breast cancers. Npj Breast Cancer 2022, 8: 119. PMID: 36344517, PMCID: PMC9640562, DOI: 10.1038/s41523-022-00492-0.
- Rozenblit M, Blenman K, Harigopal M, Reisenbichler E, Singh K, Qing T, Ibrahim E, Ramkissoon S, Asmelash S, Lin HK, Roberts M, Ross J, Huang RSP, Pusztai L. PD-L1 protein expression in relation to recurrence score values in early-stage ER + breast cancer. Breast Cancer Research And Treatment 2022, 196: 221-227. PMID: 36028784, DOI: 10.1007/s10549-022-06712-2.
- Qing T, Mohsen H, Cannataro VL, Marczyk M, Rozenblit M, Foldi J, Murray M, Townsend J, Kluger Y, Gerstein M, Pusztai L. Cancer Relevance of Human Genes. Journal Of The National Cancer Institute 2022, 114: 988-995. PMID: 35417011, PMCID: PMC9275765, DOI: 10.1093/jnci/djac068.
- Blenman KRM, Marczyk M, Karn T, Qing T, Li X, Gunasekharan V, Yaghoobi V, Bai Y, Ibrahim EY, Park T, Silber A, Wolf DM, Reisenbichler E, Denkert C, Sinn BV, Rozenblit M, Foldi J, Rimm DL, Loibl S, Pusztai L. Predictive markers of response to neoadjuvant durvalumab with nab-paclitaxel and dose dense doxorubicin/cyclophosphamide in basal-like triple negative breast cancer. Clinical Cancer Research 2022, 28: 2587-2597. PMID: 35377948, PMCID: PMC9464605, DOI: 10.1158/1078-0432.ccr-21-3215.
- Rozenblit M, Lustberg MB. Sacituzumab govitecan: ascending the treatment algorithm in triple negative breast cancer. Annals Of Translational Medicine 2022, 0: 0-0. PMID: 35530962, PMCID: PMC9073796, DOI: 10.21037/atm-22-484.
- Rozenblit M, Hofstatter E, Liu Z, O’Meara T, Storniolo AM, Dalela D, Singh V, Pusztai L, Levine M. Evidence of accelerated epigenetic aging of breast tissues in patients with breast cancer is driven by CpGs associated with polycomb-related genes. Clinical Epigenetics 2022, 14: 30. PMID: 35209953, PMCID: PMC8876160, DOI: 10.1186/s13148-022-01249-z.
- Foldi J, Rozenblit M, Park TS, Knowlton CA, Golshan M, Moran M, Pusztai L. Optimal Management for Residual Disease Following Neoadjuvant Systemic Therapy. Current Treatment Options In Oncology 2021, 22: 79. PMID: 34213636, DOI: 10.1007/s11864-021-00879-4.
- Rozenblit M, Mun S, Soulos P, Adelson K, Pusztai L, Mougalian S. Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy. Breast Cancer Research 2021, 23: 14. PMID: 33514405, PMCID: PMC7844919, DOI: 10.1186/s13058-021-01394-y.
- Rozenblit M, Huang R, Danziger N, Hegde P, Alexander B, Ramkissoon S, Blenman K, Ross JS, Rimm DL, Pusztai L. Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers. Journal For ImmunoTherapy Of Cancer 2020, 8: e001558. PMID: 33239417, PMCID: PMC7689582, DOI: 10.1136/jitc-2020-001558.
- Rozenblit M, Hendrickx W, Heguy A, Chiriboga L, Loomis C, Ray K, Darvishian F, Egeblad M, Demaria S, Marincola FM, Bedognetti D, Adams S. Transcriptomic profiles conducive to immune-mediated tumor rejection in human breast cancer skin metastases treated with Imiquimod. Scientific Reports 2019, 9: 8572. PMID: 31189943, PMCID: PMC6561945, DOI: 10.1038/s41598-019-42784-9.
- McFarland DC, Naikan J, Rozenblit M, Mandeli J, Bleiweiss I, Tiersten A. Changes in Pathological Complete Response Rates after Neoadjuvant Chemotherapy for Breast Carcinoma over Five Years. Journal Of Oncology 2016, 2016: 4324863. PMID: 27382369, PMCID: PMC4921638, DOI: 10.1155/2016/4324863.
- Suárez-Fariñas M, Ungar B, da Rosa J, Ewald DA, Rozenblit M, Gonzalez J, Xu H, Zheng X, Peng X, Estrada YD, Dillon SR, Krueger JG, Guttman-Yassky E. RNA sequencing atopic dermatitis transcriptome profiling provides insights into novel disease mechanisms with potential therapeutic implications. The Journal Of Allergy And Clinical Immunology 2015, 135: 1218-1227. PMID: 25840722, DOI: 10.1016/j.jaci.2015.03.003.
- Rozenblit M, Guttman‐Yassky E. Contact Dermatitis. 2015, 25-35. DOI: 10.1002/9781118609125.ch3.
- da Rosa J, Malajian D, Shemer A, Rozenblit M, Dhingra N, Czarnowicki T, Khattri S, Ungar B, Finney R, Xu H, Zheng X, Estrada YD, Peng X, Suárez-Fariñas M, Krueger JG, Guttman-Yassky E. Patients with atopic dermatitis have attenuated and distinct contact hypersensitivity responses to common allergens in skin. The Journal Of Allergy And Clinical Immunology 2015, 135: 712-720. PMID: 25583101, DOI: 10.1016/j.jaci.2014.11.017.
- Esaki H, Ewald DA, Ungar B, Rozenblit M, Zheng X, Xu H, Estrada YD, Peng X, Mitsui H, Litman T, Suárez-Fariñas M, Krueger JG, Guttman-Yassky E. Identification of novel immune and barrier genes in atopic dermatitis by means of laser capture microdissection. The Journal Of Allergy And Clinical Immunology 2015, 135: 153-163. PMID: 25567045, PMCID: PMC4452382, DOI: 10.1016/j.jaci.2014.10.037.
- Rozenblit M, Suarez-Farinas M, Shemer A, Khattri S, Gilleaudeau P, Sullivan-Whalen M, Zheng X, Xu H, Cardinale I, Krueger JG, Guttman-Yassky E. Residual genomic profile after cyclosporine treatment may offer insights into atopic dermatitis reoccurrence. The Journal Of Allergy And Clinical Immunology 2014, 134: 955-957. PMID: 24996261, PMCID: PMC4281263, DOI: 10.1016/j.jaci.2014.05.024.
- Khattri S, Shemer A, Rozenblit M, Dhingra N, Czarnowicki T, Finney R, Gilleaudeau P, Sullivan-Whalen M, Zheng X, Xu H, Cardinale I, de Guzman Strong C, Gonzalez J, Suárez-Fariñas M, Krueger JG, Guttman-Yassky E. Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology. The Journal Of Allergy And Clinical Immunology 2014, 133: 1626-1634. PMID: 24786238, PMCID: PMC4122665, DOI: 10.1016/j.jaci.2014.03.003.
- Dhingra N, Shemer A, da Rosa J, Rozenblit M, Fuentes-Duculan J, Gittler JK, Finney R, Czarnowicki T, Zheng X, Xu H, Estrada YD, Cardinale I, Suárez-Fariñas M, Krueger JG, Guttman-Yassky E. Molecular profiling of contact dermatitis skin identifies allergen-dependent differences in immune response. The Journal Of Allergy And Clinical Immunology 2014, 134: 362-372. PMID: 24768652, DOI: 10.1016/j.jaci.2014.03.009.
- Rozenblit M. 2011 Runner-Up Essay Incentives for Medical School Students to Practice Primary Care through the Lens of John Rawls. The AMA Journal Of Ethic 2012, 14: 970-976. PMID: 23351945, DOI: 10.1001/virtualmentor.2012.14.12.conl4-1212.
- Rozenblit M, Lebwohl M. New biologics for psoriasis and psoriatic arthritis. Dermatologic Therapy 2009, 22: 56-60. PMID: 19222517, DOI: 10.1111/j.1529-8019.2008.01216.x.
- Wang G, Drake C, Rozenblit M, Zhou P, Alves S, Herrick S, Hayashi S, Warrier S, Iadecola C, Milner T. Evidence that estrogen directly and indirectly modulates C1 adrenergic bulbospinal neurons in the rostral ventrolateral medulla. Brain Research 2006, 1094: 163-178. PMID: 16696957, DOI: 10.1016/j.brainres.2006.03.089.
- Spuls P, Rozenblit M, Lebwohl M. Retrospective study of the efficacy of narrowband UVB and acitretin. Journal Of Dermatological Treatment 2003, 14: 17-20. PMID: 14578094, DOI: 10.1080/jdt.14.s2.17.20.
- Maryles S, Rozenblit M, Lebwohl M. Transition from methotrexate and cyclosporine to other therapies including retinoids, ultraviolet light and biologic agents in the management of patients with psoriasis. Journal Of Dermatological Treatment 2003, 14: 7-16. PMID: 14578093, DOI: 10.1080/jdt.14.s2.7.16.
- Spuls P, Rozenblit M, Lebwohl M. Retrospective study of the efficacy of narrowband UVB and acitretin. Journal Of Dermatological Treatment 2003, 14: 17-20. DOI: 10.1080/738528794.
- Maryles S, Rozenblit M, Lebwohl M. Transition from methotrexate and cyclosporine to other therapies including retinoids, ultraviolet light and biologic agents in the management of patients with psoriasis. Journal Of Dermatological Treatment 2000, 14: 7-16. DOI: 10.1080/738528793.
- Maryles S, Rozenblit M, Lebwohl M. Transition from methotrexate and cyclosporine to other therapies including retinoids, ultraviolet light and biologic agents in the management of patients with psoriasis. Journal Of Dermatological Treatment 2000, 14: 7-16. DOI: 10.1080/753995509.
Departments and Programs
Locations
Smilow Cancer Hospital at Guilford
Yale New Haven Shoreline Medical Center
111 Goose Lane
Guilford, CT 06437
- Smilow Cancer Hospital at GuilfordYale New Haven Shoreline Medical Center111 Goose LaneGuilford, CT 06437
Smilow Cancer Hospital at Guilford
Yale New Haven Shoreline Medical Center
111 Goose Lane
Guilford, CT 06437
- Smilow Cancer Hospital at GuilfordYale New Haven Shoreline Medical Center111 Goose LaneGuilford, CT 06437